S

B

SLAMA , Bohrane

Last name: SLAMA

First name: Bohrane

May 7, 2011 (v1)

Journal article

Metadata-only

Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level.

Legros, Laurence Slama, Bohrane Karsenti, Jean-Michel

Myelodysplastic syndromes (MDS) are associated with increased bone marrow vascularity and increased levels of various angiogenic factors including Vascular Endothelial Growth Factor (VEGF) which is implicated in the proliferation and survival of leukemic cells. Before the approval of hypomethylating agents in this indication, the GFM conducted...

Uploaded on: December 3, 2022